Halozyme Therapeutics Inc halted a mid-stage trial testing an advanced version of its flagship drug delivery technology in patients with pancreatic cancer, sending its shares tumbling 32 percent. The biotechnology company said it halted enrollment and patient dosing as a "precautionary measure" following the recommendation of an independent safety committee. The pancreatic cancer study was testing a more potent form of the company's existing technology to deliver chemotherapy drugs intravenously and to prolong the effectiveness of its synthetic enzyme, Hylenex, in the blood stream. Halozyme said on Friday the committee is assessing a possible difference in the rate of blood clots found in patients receiving its treatment against those receiving approved cancer treatments. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment